BDBM572192 (rac)-4-chloro-3-ethyl-14-methyl-1-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl}-10,11,12,13,14,15-hexahydro-1H-pyrazolo[3′,4′:8,9][1,6]diazacycloundecino[10,11,1-hi]indole-8-carboxylic Acid::US11447504, Example 45::US11447504, Example 46::US11447504, Example 47::US11478451, Example 47

SMILES CCc1nn(CCN2CCOCC2)c2CN(C)CCCCn3c(C(O)=O)c(CCCOc4cccc5ccccc45)c4ccc(Cl)c(-c12)c34

InChI Key InChIKey=GHFRJMORTHPRRF-UHFFFAOYSA-N

Data  14 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 572192   

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572192((rac)-4-chloro-3-ethyl-14-methyl-1-[2-(morpholin-4...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent